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Abstract
Purpose The purposes of this study were to estimate the inci-
dence of chemotherapy-induced peripheral neuropathy
(CIPN) and to identify its main determinants and impact in
patient-reported outcomes.
Methods We performed a prospective cohort study including
296 patients with incident breast cancer submitted to chemo-
therapy, followed for 1 year. Patients with incident CIPN were
reevaluated 6 months after this diagnosis. Relative risks (RR)
with 95 % confidence intervals (95 % CI) were computed to
quantify the relation between different clinical characteristics
and the occurrence of CIPN, using Poisson regression. The
variation of patient-reported outcomes between baseline and
1-year follow-up assessments was compared between patients
with and without CIPN.
Results The cumulative incidence of CIPN in the first year
after diagnosis was 28.7 % (95 % CI 23.8–34.1), and more
than 80 % of the patients were still symptomatic after
6 months. Among the latter, there was a significant decrease
in the median total neuropathy score, clinical version (7 versus
4) between the two periods. In multivariable analysis, the risk
of CIPN was higher for treatment with docetaxel (cumulative
doses ≤300 mg/m2, RR=6.96, 95% CI 2.53–19.10; >300mg/
m2, RR=13.32; 95 % CI 4.11–43.14). Alcohol consumption
and diabetes were not significantly associated with CIPN.
There were no significant differences in the variation of
patient-reported outcomes between the baseline and 1-year
follow-up evaluations.
Conclusions CIPN was frequent in this contemporary cohort
of early-stage breast cancer patients and was strongly associ-
ated with docetaxel-based regimens. Symptoms persisted for
at least 6 months in most patients, but severity was low and
CIPN had no impact on patient-reported outcomes.
Keywords Breast neoplasm . Peripheral nerve injuries .
Quality of life
Introduction
Breast cancer is the most frequent cancer in women, with an
estimated 1.7 million new cases diagnosed in 2012 [1] and is
among those with better survival (the 5-year relative survival
is higher than 80 % in most developed countries [2, 3]). The
growing number of women living for increasingly long pe-
riods after the diagnosis of breast cancer highlights the need of
a comprehensive assessment of the burden of the disease re-
lated with breast cancer treatments among survivors.
Chemotherapy-induced peripheral neuropathy (CIPN) is one
of the most frequent adverse effects of many commonly used
chemotherapeutic agents [4], with potential impact on the pa-
tients’ quality of life (QoL) [5, 6].
CIPN involve the peripheral nervous system and lead to
predominantly sensory peripheral neuropathy, with a
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Bstocking and glove^ distribution characterized by sensory
loss, paresthesia, numbness, and tingling, that may be aggra-
vated by neuropathic pain [7, 8]. Treatments associated with a
higher incidence of CIPN include those with platinum drugs,
vinca alkaloids, or taxanes [9]. The estimated occurrence of
CIPN among patients undergoing chemotherapy varied wide-
ly across previous investigations, largely reflecting differences
in study designs, populations studied, specificities of the treat-
ment schemes, and lack of uniformity in CIPN assessment
methods [10–14].
Preexisting peripheral neuropathies, namely due to diabe-
tes or excessive alcohol consumption have been considered
risk factor for CIPN. Although these associations seem plau-
sible, because such conditions can cause a neuropathy similar
to CIPN, their role as risk factors for CIPN is not yet demon-
strated since most previous investigations excluded these pa-
tients and the few existing studies have conflicting results
[15–18] and, to our knowledge, the available results do not
refer specifically to breast cancer patients.
A prospective study with a systematic neurological evalu-
ation of patients during different moments of the first year
after breast cancer diagnosis, and a standardized clinical as-
sessment and characterization of CIPN among patients in ear-
ly stages, treated with different chemotherapy schemes, may
contribute to a better understanding of the burden of this neu-
rological complication. Therefore, we aimed to estimate CIPN
incidence and to identify its main determinants and impact in
different patient-reported outcomes.
Methods
Study design and participants
We conducted a prospective cohort study of women consecu-
tively recruited in 2012 among those with newly diagnosed
breast cancer admitted to the Breast Clinic of the Portuguese
Institute of Oncology of Porto, Portugal. The study methods
have been described in detail elsewhere [19]. Briefly, we con-
secutively selected women proposed for surgery, either as pri-
mary treatment or after neoadjuvant chemotherapy, whose
follow-up would go on to occur in the same hospital. We
excluded those previously treated for cancer, submitted to
breast surgery, with stage IV breast cancer, and those scoring
less than 17, or less than 16 for women over 65 years old in the
Montreal Cognitive Assessment (MoCA), which was as-
sumed to correspond to a high probability of cognitive impair-
ment [20].
The cohort included 502 patients with incident breast can-
cer, from whom 296 (59.0 %) underwent neoadjuvant or ad-
juvant chemotherapy in the first year after diagnosis and there-
fore were considered for the present analysis.
Data collection
All patients underwent a neurological evaluation and
sociodemographic and medical data were collected at baseline
(before any treatment), 2 weeks after surgery, 3 weeks after the
last cycle of chemotherapy, and 1 year after enrolment. Pa-
tients diagnosed with CIPN during the first year of follow-up
were also evaluated at the moment of CIPN confirmation and
after 6 months, in order to define the chronicity of such
condition.
At baseline, information on the consumption of alcoholic
beverages and previous diagnosis of diabetes or thyroid pa-
thology was obtained from the patients and/or review of their
medical records. Self-report or record of either a previous
diagnosis or treatment with insulin or oral antidiabetic drugs
were considered to classify patients as having diabetes. Indi-
viduals drinking at least one alcoholic drink per month were
classified as current drinkers and those who stopped drinking
at least 6 months before the interview as former drinkers.
Current drinkers were further classified according to the
amount of ethanol consumed; for this purpose, we considered
that a standard drink corresponds to 14 g of ethanol.
Preexisting cases of peripheral neuropathy were identified
at the baseline neurological assessment. During the remaining
evaluations, data about breast cancer stage, surgery, chemo-
therapy (including chemotherapy schemes and total dose de-
livered), and other adjuvant treatments performed were col-
lected from clinical records by clinicians.
Patient-reported outcomes were evaluated before any treat-
ment and at 1 year after enrolment. QoL was assessed using
the self-administered questionnaire of the European Organiza-
tion for the Research and Treatment of Cancer (EORTC)
(QLQ-C30) [21]; the specific global health status/QoL sub-
scale was used for the purpose of this study. Sleep quality was
evaluated using the Pittsburg SleepQuality Index (PSQI) [22].
Anxiety and depression were evaluated using the Hospital
Anxiety and Depression Scale (HADS) [23]. For the global
health status/QoL subscale, higher scores represent a healthier
level of QoL, while in the remaining instruments, higher
scores correspond to worse outcomes.
Outcome definition
CIPN was defined as peripheral neuropathy beginning after
chemotherapy; among patients with preexisting peripheral
neuropathy, CIPN was considered to have occurred only if
there was a worsening of neuropathy after the beginning of
chemotherapy. CIPN was quantified using the Common Ter-
minology Criteria for Adverse Events version 4.0 (CTCAE
v4.0) [24] and the Total Neuropathy Score, clinical version
(TNSc) [25]. The latter requires that strength, deep tendon
reflexes, vibration sensibility (128-Hz tuning fork), and pain
sensation (wood cocktail-stick) are evaluated to quantify the
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severity of neuropathy. The classification system proposed by
the International Association for the Study of Pain (IASP) was
used in order to classify painful CIPN [26].
Incident cases of CIPN were identified through referral by
any member of the clinical team or during the systematic
neurological evaluations performed by neurologists. Cases
identified at the time of the scheduled follow-up evaluations
were assigned an estimated date of onset based on information
provided by the patients. When applicable, information re-
garding chemotherapy interruption or dose reduction was re-
trieved from records.
Statistical analysis
We computed cumulative incidence estimates for CIPN at the
1-year follow-up and the corresponding 95 % confidence in-
tervals (95 % CI).
Crude and adjusted relative risks (RR) and corresponding
95 % CI for the relation between different characteristics of
the patients and the occurrence of CIPN in the first year after
enrolment were computed using Poisson regression; variables
included in each model are described in the footnotes of the
corresponding table.
Standardized scores (z scores) of the variation in patient-
reported outcomes between the baseline assessment and the 1-
year follow-up evaluation were computed.
Statistical analysis was conducted using STATA®, version
11.2 (StataCorp, College Station, TX, USA).
Results
Figure 1 depicts the number of patients in each evaluation
performed. From those who underwent chemotherapy, one
patient abandoned the study (no reason specified), and 295
(99.7 %) completed the 1-year follow-up evaluation. A total
of 85 patients were diagnosed with CIPN and all completed
the 6-month evaluation after diagnosis.
Patients’ characteristics
The main demographic and medical characteristics of the par-
ticipants are presented in Table 1. At baseline, 46.0 % were
aged less than 50 years and 70.3 % had up to 9 years of
education. Approximately one third of women were diag-
nosed with breast cancer stage I, and most patients performed
chemotherapy as adjuvant treatment (88.8 %). The most fre-
quent chemotherapy scheme performed was FEC-D [three
cycles of concomitant 5-fluorouracil (5-FU) 500 mg/m2,
epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2
followed by three cycles of docetaxel 100 mg/m2]. In addition
to chemotherapy, endocrine therapy and radiotherapywere the
most common adjuvant treatments (83.7 and 83.4 %,
respectively).
Incidence and characterization of CIPN
During the first year after the diagnosis of breast cancer,
28.7 % (95 % CI 23.8–34.1) of the patients were diagnosed
with CIPN. Among those submitted to docetaxel-based regi-
mens, the cumulative incidence was 38.0 % (95 % CI 31.8–
44.7). The median [percentile 25–percentile 75 (P25–P75)]
time to CIPN onset since the beginning of chemotherapy
was 107 (84–122) days.
At the moment of CIPN diagnosis, all patients presented
peripheral sensory neuropathy grade 1 or 2 but only 18.8 %
had motor neuropathy (grade 1 to 3), according to the CTCAE
v4.0; the TNSc ranged between 3 and 12 (Table 2). Five pa-
tients presented painful CIPN, classified as probable accord-
ing to the IASP; only one patient required dose reduction due
296 paents underwent chemotherapy
Neoadjuvant chemotherapy
(N=33)
1 paent abandoned
the study
295 paents completed the 1-year follow-up evaluaon
Follow-up: [Median(P25-P75): 369 (362-381) days];
Follow-up since onset of neoadjuvant chemotherapy: [Median(P25-P75): 360 (349-368) days];
Follow-up since onset of adjuvant chemotherapy: [Median(P25-P75): 306 (282-323) days].
Adjuvant chemotherapy
(N=263)
85 paents completed the 6-month follow-up evaluaon
Follow-up: [Median(P25-P75): 187 (176-201) days];.
85 paents diagnosed with CIPN
Fig. 1 Flow chart describing the
number of patients in each of the
evaluations performed. CIPN
chemotherapy-induced peripheral
neuropathy, P25 percentile 25,
P75 percentile 75
Support Care Cancer (2016) 24:1571–1581 1573
Table 1 Demographic and medical characteristics of the breast cancer patients submitted to chemotherapy (N=296)
N (%)a
Age, years [mean (SD)] 52.0 (10.1)
Age, years <50 136 (46.0)
≥50 160 (54.0)
Education, years [median (P25–P75)] 6.0 (4.0–11.5)
Education, years ≤4 103 (34.8)
5–9 105 (35.5)
10–12 47 (15.9)
>12 41 (13.8)
Medical comorbidities Thyroid pathology 41 (13.8)
Diabetes 20 (6.8)
Preexisting peripheral neuropathy 2 (0.7)
Cancer stage at baseline I 95 (32.1)
II 132 (44.6)
III 69 (23.3)
Surgery
Breast surgeryb Mastectomy 165 (55.7)
Breast-conserving 131 (44.3)
Axillary surgeryc ALND 154 (52.0)
SLNB 142 (48.0)
Chemotherapy
Timing of chemotherapy Neoadjuvant 33 (11.2)
Adjuvant 263 (88.8)
Chemotherapy schemesd Doxorubicin+cyclophosphamidee 57 (19.3)
Doxorubicin+cyclophosphamide+docetaxelf 32 (10.8)
Doxorubicin+cyclophosphamide+paclitaxelg 1 (0.3)
Cyclophosphamide+docetaxelh 2 (0.7)
Carboplatin+docetaxeli 1 (0.3)
5-FU+epirubicin+cyclophosphamidej 24 (8.1)
5-FU+epirubicin+cyclophosphamide+docetaxelk 178 (60.1)
5-FU+cyclophosphamide+methotrexatel 1 (0.3)
Other adjuvant treatments [N=295m] Radiotherapy 246 (83.4)
Brachytherapy 43 (14.5)
Endocrine therapy 247 (83.7)
Immunotherapy 68 (23.0)
ALND axillary lymph node dissection, P25 percentile 25, P75 percentile 75, SD standard deviation, SLNB sentinel lymph node biopsy, 5-FU 5-
fluorouracil
a Results are presented as N (%), except if otherwise specified
b Patients who had both mastectomy and breast-conserving surgery are reported as mastectomy
c Patients who had both ALND and SLNB are reported as ALND
dDoes not sum 100.0 % due to rounding
e Four cycles of concomitant doxorubicin (60 mg/m2 ) and cyclophosphamide (600 mg/m2 )
f Four cycles of concomitant doxorubicin (60 mg/m2 ) and cyclophosphamide (600 mg/m2 ), followed by four cycles of docetaxel (100 mg/m2 )
g Four cycles of concomitant doxorubicin (60 mg/m2 ) and cyclophosphamide (600 mg/m2 ), followed by four cycles of paclitaxel (80 mg/m2 )
h Four cycles of concomitant cyclophosphamide (600 mg/m2 ) and docetaxel (75 mg/m2 )
i Six cycles of concomitant docetaxel (75 mg/m2 ) and carboplatin (212 mg/m2 )
j Six cycles of concomitant 5-FU (500 mg/m2 ), epirubicin (100 mg/m2 ), and cyclophosphamide (500 mg/m2 )
k Three cycles of concomitant 5-FU (500 mg/m2 ), epirubicin (100 mg/m2 ), and cyclophosphamide (500 mg/m2 ) followed by three cycles of docetaxel
(100 mg/m2 )
l Six cycles of concomitant 5-FU (600 mg/m2 ), cyclophosphamide (600 mg/m2 ), and methotrexate (40 mg/m2 )
mData is only available for patients who completed the 1-year follow-up evaluation
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to CIPN and there were no cases of discontinuation related to
CIPN.
Predictors of CIPN during the first year of follow-up
Table 3 presents RR for the relation between different
characteristics of the patients and the occurrence of
CIPN during the first year after enrolment. Compared
to chemotherapy schemes with no docetaxel, patients
treated with a cumulative dose of docetaxel ≤300 mg/
m2 had a nearly sevenfold higher risk of CIPN (RR=
6.96; 95 % CI 2.53–19.10), and among those receiving
>300 mg/m2, the risk was more than 13 times higher
(RR=13.32; 95 % CI 4.11–43.14).
In multivariate analyses, cancer stage III (RR=2.45; 95 %
CI 1.36–4.04), axillary lymph node dissection (ALND) (RR=
2.28; 95 % CI 1.23–4.25), and immunotherapy (RR=1.96;
95 % CI 1.24–3.09) were also associated with a higher risk
of CIPN. However, after adjusting for chemotherapy drugs,
cancer stage III (RR=1.01; 95%CI 0.51–1.98), ALND (RR=
1.24; 95 % CI 0.65–1.98), and immunotherapy (RR=1.43;
95 % CI 0.88–2.33) were no longer associated with the occur-
rence of CIPN.
Diabetes and alcohol consumption habits at baseline were
not significantly associated with the occurrence of CIPN
(Table 3), and the RR estimates for the relation between
docetaxel-based chemotherapy and CIPN did not change
meaningfully when further adjusted for diabetes or alcohol
consumption (7.22 vs. 7.09).
Impact of CIPN in patient-reported outcomes at 1-year
follow-up
The variation of z scores of patient-reported health-related
outcomes, between the baseline and the 1-year follow-up as-
sessment, according to the presence of CIPN is represented in
Fig. 2. There were no statistically significant differences in the
variation between the twomoments of evaluation according to
the presence of CIPN. Also, there were no statistically signif-
icant differences in the variation of any of the patient reported
outcomes according to the presence of motor neuropathy or
the severity of CIPN (data not shown).
CIPN during the 6-month follow-up of CIPN patients
A total of 70 (82.4 %, 95 % CI 72.8–89.1) of all patients with
CIPN remained symptomatic to the end of the follow-up of the
subcohort.
As depicted in Table 2, among those symptomatic at the 6-
month follow-up, there was a decrease in the severity of motor
(present in 18.6 and 7.1 % of the patients at baseline and
follow-up, respectively; P=0.057) and sensory symptoms
(grade 2 in 38.6 and 21.4 % of the patients at baseline and
follow-up, respectively; P=0.017) during the follow-up. The
Table 2 Classification of chemotherapy-induced peripheral neuropathy (N=85)
N (%)a
All patients with a diagnosis of CIPN (N=85) Patients with CIPN lasting at least 6 months (N=70)
Baseline Baseline 6-month follow-up P value
Peripheral motor neuropathy
(according to CTCAE v4.0)
Absent 69 (81.2) 57 (81.4) 65 (92.9)
Present 16 (18.8) 13 (18.6) 5 (7.1)
Grade 1 10 (11.8) 7 (10.0) 4 (5.7)
Grade 2 5 (5.9) 2 (7.1) 0 (0.0) 0.057b
Grade 3 1 (1.2) 1 (1.4) 1 (1.4)
Peripheral sensory neuropathy
(according to CTCAE v4.0)
Absent 0 (0.0) 0 (0.0) 1 (1.4)
Present 85 (100.0) 70 (100.0) 69 (98.6)
Grade 1 57 (67.1) 43 (61.4) 54 (77.1)
Grade 2 28 (32.9) 27 (38.6) 15 (21.4) 0.017c
Total neuropathy score
Median (P25–P75) 6 (5–9) 7 (5–9) 4 (2–6) <0.001
Range 3 to 12 3 to 12 1 to 13
CTCAE v4.0 Common Terminology Criteria for Adverse Events, version 4.0, P25 percentile 25, P75 percentile 75
a Results are presented as N (%), except if otherwise specified
bMcNemar exact test for the comparison of the proportion of patients with motor symptoms
cMcNemar exact test for the comparison of the proportion of patients with sensory symptoms grade 2
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median (P25–P75) TNSc decreased significantly from 7 (5–9)
to 4 (2–6).
In crude and multivariate analyses, sociodemographic and
medical characteristics (including breast cancer treatments)
and patient-reported outcomes at baseline were not associated
with higher risk of CIPN after 6 months of the diagnosis of
this complication (data not shown).
Discussion
The present study provides a comprehensive assessment of the
clinical epidemiology of CIPN after neoadjuvant and adjuvant
treatments of breast cancer, in a contemporary cohort of wom-
en with early-stage cancer. Important strengths of this inves-
tigation are the nearly complete follow-up of the main cohort
and a complete follow-up of the CIPN patients. Furthermore,
the use of the TNSc to grade CIPN has the advantage of
including an objective nerve function examination [25, 27].
Peripheral neuropathy is a major complication of both diabe-
tes and alcoholism and both have been assumed in the litera-
ture as risk factors for CIPN [28, 29]. To our knowledge, this
is the first prospective study addressing diabetes and alcohol
consumption as risk factors for CIPN in breast cancer patients.
However, we did not find a significant association between
these two exposures and CIPN or its severity (data not
shown). These results suggest that alcohol consumption and
diabetes have no important effect in the occurrence of CIPN,
at least among patients with relatively low alcohol intake and
type 2 controlled diabetesmellitus, such as those in the present
cohort. Unfortunately, it was not possible to assess the effect
of previous neuropathy in the occurrence of CIPN because the
number of patients with neuropathy at baseline was too small.
There were only two patients with mild diabetic neuropathy
diagnosed at baseline, and these were not treated with
docetaxel.
Nearly 30 % of the patients developed CIPN within
1 year of breast cancer diagnosis, and the cumulative in-
cidence of docetaxel-induced peripheral neuropathy was
38.0 %. Our data yielded estimates of the frequency of
docetaxel-induced peripheral neuropathy similar to those
found by other authors in Denmark [30, 31], but in our
cohort all women with CIPN had sensory symptoms up to
grade 2, whereas in the former investigations, the propor-
tion of cases graded higher than 2 was 7.7 % [31] and
32.5 % [30]. However, one of these studies excluded
women with sensory neuropathy grade 1 and relied on
self-reports to define CIPN [30], the other identified and
characterized CIPN using retrospective clinical record data
[31], and both used version 2.0 of the CTCAE to assess
the severity of CIPN. Regarding motor symptoms, its oc-
currence has been described to be less frequent than sen-
sory neuropathy [4, 32], which was in accordance with
our results.
Higher doses per cycle [30] and cumulative doses over
600 mg/m2 [28] have been described as risk factors for
docetaxel-induced peripheral neuropathy, though a more re-
cent study, with patients that underwent cumulative doses less
than 450 mg/m2, did not find a dose-response relationship
[30]. In our cohort, compared to chemotherapy schemes with
no docetaxel, patients treated with a cumulative dose of doce-
taxel ≤300 mg/m2 had a nearly sevenfold higher risk of CIPN,
and the RR was just over 13 times higher for those receiving
>300 mg/m2. Unfortunately, the present study does not allow
an assessment of the impact of dose-dense regimens in the
incidence of CIPN since the use of this treatment strategy in
the institution where patients were recruited started approxi-
mately 2 years after the baseline assessment.
A systematic review addressing the role of CIPN on
QoL among cancer patients found a probable negative
association with QoL [33]. Of the 11 studies assessing
the association of CIPN on patients’ QoL, three did not
find an association and the others concluded that CIPN
was associated with a lower QoL. However, none of the
studies included specifically women with breast cancer.
A recent study in early breast cancer patients that
underwent chemotherapy with docetaxel found that the
persistence of CIPN 1–3 years after treatment had a
significant negative correlation with health-related QoL
[6]. In our study, we did not find a significant impact of
CIPN in patient-reported outcomes at 1-year of follow-
up, which can be related with the lower severity of
docetaxel CIPN and the fact that patients improved over
this period.
Despite the contribution of the present study to an accurate
characterization of the occurrence of CIPN among early-stage
Fig. 2 Variation in patient-reported outcomes between the baseline and
the 1-year follow-up assessment, according to the presence of CIPN.
Superscript a, Mann-Whitney U test. CIPN chemotherapy-induced pe-
ripheral neuropathy
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breast cancer patients, some limitations need to be addressed.
Although nerve conduction studies (NCS) are considered the
goal standard for CIPN diagnosis, the previous prospective
studies using these methods to evaluate CIPN in breast cancer
patients receiving chemotherapy with taxanes included a
small number of breast cancer patients [34–36], reflecting
the fact that NCS are time and resource consuming. Our study
was based on a cohort of a large number of participants,
assembled and followed in a clinical setting, which pre-
cludes complex evaluations such as NCS. Nevertheless, it
is important to emphasize that we assessed CIPN using
the TNSc, which incorporates not only subjective but also
objective items [25, 27]. A recent article from the
chemotherapy-induced peripheral neuropathy outcome
measure standardization study (CI-PeriNomS) concluded
that vibratory sensation and light touch are associated with
abnormal sural nerve amplitudes, suggesting that these
components of neurological exam are reliable indicators
of CIPN [37]; these two measures are included in TNSc
score used in our study. We excluded patients with stage
IV and those not submitted to surgical treatment, which
limits the generalization to patients with more advanced
disease. Furthermore, all patients were selected from the
same institution, the Portuguese Institute of Oncology of
Porto. However, this is the largest hospital providing care
to oncological patients in the north of Portugal, treating
patients from a wide geographical area, which may help to
mitigate the latter limitation. Previous studies have shown
that subclinical deficits in sensory function may be present
among patients with colorectal cancer [38, 39] and mye-
loma [40, 41] even before initiating any therapy, and
CIPN may correspond to an exacerbation of this
preexisting condition. In our study, although all patients
underwent a neurological examination before breast cancer
treatment, to exclude clinical neuropathy, we did not per-
form quantitative sensory testing, and therefore, we cannot
exclude the presence of subclinical deficits in sensory
function before treatments. Future studies should address
the role of these preexisting conditions as an effect mod-
ifier of the association between chemotherapy and CIPN.
The participants in our study were followed for 6 months
after the diagnosis of CIPN, and a longer follow-up will
allow the comparison with studies with longer follow-up
[42]. Previous studies addressed the effect of interventions
to prevent CIPN [43–45], but no such exposures were
observed in our cohort.
In conclusion, CIPN was frequent in this prospective co-
hort study of early-stage breast cancer patients andwas strong-
ly associated with docetaxel-based regimens. Symptoms
persisted for at least 6 months in most patients, but severity
was usually low; painful CIPN, and dose reduction due to
CIPN were observed in a small number of patients, and CIPN
had no impact on patient-reported outcomes. The results from
this study are useful to support clinical decisions related with
the use of docetaxel-based chemotherapy.
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